(Q45218145)

10 December 2017

Reduction of body weight and co-morbidities by orlistat: The XXL--Primary Health Care Trial (English)

1 reference

10 December 2017

Wirth A

1

1 reference

10 December 2017

1 January 2005

1 reference

Diabetes, Obesity and Metabolism

10 December 2017

1 reference

10 December 2017

7

1 reference

10 December 2017

1

1 reference

10 December 2017

21-27

1 reference

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

10 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00428.X

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00428.X

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00428.X

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00428.X

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00428.X

Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2004.00428.X

10.1111/J.1463-1326.2004.00428.X

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference

PubMed ID

15642072